Death (any cause) (median · adults with kidney failure treated with long‐term HD
Low molecular weight heparin showed no clear difference in death (any cause) Median compared with unfractionated heparin (low certainty).
1 finding from 1 review
Dialysis vascular access thrombosis Median · adults with kidney failure treated with long‐term HD
Low molecular weight heparin showed no clear difference in dialysis vascular access thrombosis Median compared with unfractionated heparin (low certainty).
1 finding from 1 review
Dialysis vascular adequacy (Kt/V) · adults with kidney failure treated with long‐term HD
1 finding from 1 review
Minor bleeding · adults with kidney failure treated with long‐term HD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood transfusion · adults with kidney failure treated with long‐term HD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Outcomes · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · patients with cancer with venous thromboembolism
Low molecular weight heparin showed no clear difference in mortality compared with unfractionated heparin (low certainty).
1 finding from 1 review
Recurrent VTE · patients with cancer with venous thromboembolism
Low molecular weight heparin showed no clear difference in recurrent VTE compared with unfractionated heparin (low certainty).
1 finding from 1 review
Major bleeding · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding ‐ not reported · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not reported · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Postphlebitic syndrome ‐ not reported · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Heparin changes incidence of hepatic veno‐occlusive disease ( compared with low molecular weight heparin (very low certainty).
1 finding from 1 review
Overall survival · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with low molecular weight heparin (very low certainty).
1 finding from 1 review
Quality of life · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of adverse events ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Heparin changes frequency of adverse events ( compared with low molecular weight heparin (very low certainty).
1 finding from 1 review
Deep vein thrombosis · participants at risk of venous thromboembolism
Combined NMES and low‐dose heparin may leads to lower total DVT compared with low‐dose heparin (low certainty).
1 finding from 1 review